Evaluation for Efficacy of Rosuvastatin on Carotid Intima Media Thickness and Characteristics of Atherosclerosis in Hyperlipidemic Patients with Type 2 Diabetes

Evaluation for Efficacy of Rosuvastatin on Carotid Intima Media Thickness and Characteristics of Atherosclerosis in Hyperlipidemic Patients with Type 2 Diabetes - Evaluation for Efficacy of Rosuvastatin on Carotid Intima Media Thickness and Characteristics of Atherosclerosis in Hyperlipidemic Patients with Type 2 Diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017198

Enrollment

Registered

2015-04-27

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipidemic patients with type 2 diabetes

Interventions

Rosuvastatin drug was administered at a dose of 5 mg for 52 weeks to hyperlipidemic patients with type 2 diabetes with max-IMT over 1.1 mm despite prior oral administration of a low-intensity statin f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hyperlipidemic patients with type 2 diabetes who had been treated with a low oral dose of a strong or a mild statin (Pitavastatin 1mg, Atorvastatin 5mg, Pravastatin, Simvastatin, Fluvastatin) for 3 months or more were enrolled (with max-IMT over 1.1 mm )

Exclusion criteria

Exclusion criteria: (1)Receiving fibrates (2)Hemodialysis (3)Familial hypercholesterolemia (4)Onset a cerebrovascular accident during the preceding period of less than 3 months (5)Severe liver dysfunction (AST over 100IU/L, ALT over 100IU/L, Total bilirubin over 2.5mg/dl) (6)Severe renal dysfunction (serum creatinine over 2.0mg/dl, Ccr 30mL/min (7)Creatine Kinase over 500IU/L (8)Receiving cyclosporine (9)Pregnant or possibly pregnant (10)Hypothyroidism or hereditary myopathy, a family history of these diseases, and a past history of drug-induced myopathy (11)Drug abuse or alcoholism (12)Malignancy (13)Serious complications

Design outcomes

Primary

Measure	Time frame
changes in low-density lipoprotein (LDL) levels after 52 weeks of treatment were analyzed	—

Secondary

Measure	Time frame
mean-IMT, maximal IMT (max-IMT), and max-IMT of the common carotid artery (CCA max-IMT), and ABI (ankle-branchial index), and CAVI(cardio ankle vascular index) after 52 weeks of treatment were analyzed	—

Countries

Japan

Contacts

Public ContactTAKANORI KUDO

Hachinohe City Hospital Department of Endocrinology and Diabetes

t-ku-do@pb3.so-net.ne.jp0178-72-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026